Answers are grounded in this paper and cite their sources.
In this study we retrospectively reviewed dupilumab’s efficacy and safety profile in treating elderly patients with atopic dermatitis (AD) and explored the predictive indicators for its efficacy. After analysing data from 181 patients we found that dupilumab appears to be effective and well-tolerated in treating AD among elderly patients. More importantly, we found that disease severity and early response to dupilumab are associated with complete remission at week 24 and may be used as potential predictive indicators for dupilumab’s efficacy.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: